NT-0527

Overview

NT-0527 is a selective, orally active, and brain-permeable NLRP3 inflammasome inhibitor. NT-0527 can specifically block the formation of the NLRP3 inflammasome, resulting in the reduction in the maturation and release of IL-1β , exhibit inhibition on CYP2C19 . NT-0527 displays anti-inflammatory activity in the mouse LPS ( HY-D1056 ) /ATP ( HY-B2176 )-induced peritonitis model. NT-0527 can be used for the research of neuroinflammatory disorders (Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis) and peripheral inflammatory disorders (type II diabetes, atherosclerosis, gout, etc.) associated with NLRP3 inflammasome.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Amyotrophic Lateral Sclerosis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > NOD-like Receptor (NLR) | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Cytochrome P450

Product Information

• Catalog No.: HY-186072
• CAS No.: 2771019-10-2
• Molecular Formula: C17H14ClFN4O2
• Molecular Weight: 360.77
• Purity: 99.80%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source